Nexentis Technologies Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Forward-Looking Statements
Certain information set forth in this Quarterly Report on Form 10-Q (the “Quarterly Report”) including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:
| ● | Our efforts to complete and integrate current and/or future acquisitions and joint ventures, which could disrupt our current business activities and adversely affect our results of operations or future growth; |
|---|---|
| ● | Regulatory and compliance changes may adversely impact Solterra’s operations and our joint venture value; |
| ● | Joint venture and partnership risks may affect Solterra’s projects and our joint venture value; |
| ● | Our ability to successfully develop and commercialize MitoCareX’s products and obtain required regulatory approvals; |
| ● | Our ability to obtain the additional capital required to fund MitoCareX’s development programs; |
| ● | Operational and business opportunities available to us following the acquisition of MitoCareX; |
| ● | Our relationships with third parties, including those that support MitoCareX’s operations; |
| ● | International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States or Israel; |
| ● | The evolution of our business strategy may not be successful and we may require additional financing, have increased operational costs or experience other financial harm to our business and financial condition; |
| ● | The effects of geopolitical events, including instability or the escalation of armed conflicts in the Middle East, including the security situation in Israel; |
| ● | Our ability to attract and retain sufficient, qualified personnel; |
| ● | Our ability to obtain or maintain patents or other appropriate protection for the intellectual property; |
| ● | Our ability to adequately support future growth; |
| ● | Potential product liability or intellectual property infringement claims; |
| ● | Portfolio concentration; |
| ● | Our ability to comply with the continued listing requirements of the Nasdaq Capital Market; |
| ● | The market price of our common stock; |
| ● | International expansion of our business and operations; and |
| ● | Information with respect to any other plans and strategies for our business. |
These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Readers are urged to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.
As used in this Quarterly Report and unless otherwise indicated, the terms “Nexentis,” “we,” “us,” “our,” or “our company” refer to Nexentis Technologies Inc., and Save Foods Ltd., our former 98.48% owned subsidiary (“Save Foods”), and MitoCareX Bio Ltd., our wholly owned subsidiary (“MitoCareX”) and our wholly owned subsidiary, NITO Renewable Energy, Inc. (“NITO Renewable”), which owns 70% of SB Storage 1 S.R.L.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.